Stonegate Investment Group LLC Has $443,000 Position in Haleon plc (NYSE:HLN)

Stonegate Investment Group LLC grew its stake in Haleon plc (NYSE:HLN) by 23.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 46,428 shares of the company’s stock after purchasing an additional 8,720 shares during the quarter. Stonegate Investment Group LLC’s holdings in Haleon were worth $443,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Dimensional Fund Advisors LP lifted its position in Haleon by 2.5% during the second quarter. Dimensional Fund Advisors LP now owns 1,007,458 shares of the company’s stock worth $8,322,000 after acquiring an additional 24,673 shares during the last quarter. Hsbc Holdings PLC increased its stake in shares of Haleon by 132.6% during the second quarter. Hsbc Holdings PLC now owns 35,876 shares of the company’s stock worth $296,000 after purchasing an additional 20,449 shares during the period. Sei Investments Co. lifted its holdings in Haleon by 2.7% during the 2nd quarter. Sei Investments Co. now owns 802,507 shares of the company’s stock worth $6,629,000 after purchasing an additional 21,418 shares during the last quarter. Bank of Montreal Can boosted its stake in Haleon by 10.4% in the 2nd quarter. Bank of Montreal Can now owns 742,564 shares of the company’s stock valued at $6,379,000 after purchasing an additional 69,939 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in Haleon by 95.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,954,304 shares of the company’s stock valued at $16,143,000 after buying an additional 954,622 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on HLN. UBS Group raised Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. Sanford C. Bernstein downgraded shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Finally, Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Stock Down 0.8 %

Shares of NYSE HLN opened at $9.51 on Wednesday. Haleon plc has a 52 week low of $7.89 and a 52 week high of $10.80. The stock’s fifty day moving average is $9.54 and its 200 day moving average is $9.75. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a market capitalization of $43.03 billion, a P/E ratio of 27.96, a PEG ratio of 2.60 and a beta of 0.29.

Haleon (NYSE:HLN) last released its earnings results on Thursday, October 31st. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.11 by $0.03. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The firm had revenue of $3.62 billion for the quarter, compared to analyst estimates of $3.74 billion. During the same period last year, the firm earned $0.10 EPS. Sell-side analysts forecast that Haleon plc will post 0.44 earnings per share for the current fiscal year.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.